On April 29, 2025, Travere Therapeutics announced that the European Commission has granted standard marketing approval for FILSPARI® to treat adults with primary IgA nephropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use. This approval allows the company to receive a $17.5 million milestone payment and opens opportunities for additional payments based on market achievements.